Triple Combination Inhaler

About Chiesi USA

Chiesi USA is a commercial-stage, specialty pharmaceutical company and a key subsidiary of the Italy-based Chiesi Group. It operates with a dual therapeutic focus on Special Care (including neonatology and critical care) and Rare Diseases, leveraging its global parent's R&D capabilities. The company is actively advancing its pipeline, notably with a triple-combination inhaler for asthma under FDA review, while maintaining a strong commitment to environmental and social responsibility. As a private, family-owned entity, it combines long-term strategic vision with a dedicated commercial presence in the competitive U.S. market.

Therapeutic Areas

Other Maintenance Treatment of Asthma Drugs